1. Home
  2. TFIN vs NTLA Comparison

TFIN vs NTLA Comparison

Compare TFIN & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TFIN

Triumph Financial Inc.

HOLD

Current Price

$61.99

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$13.47

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TFIN
NTLA
Founded
1981
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
TFIN
NTLA
Price
$61.99
$13.47
Analyst Decision
Hold
Buy
Analyst Count
5
23
Target Price
$66.20
$20.02
AVG Volume (30 Days)
260.7K
6.9M
Earning Date
04-21-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.43
EPS
N/A
N/A
Revenue
N/A
$67,671,000.00
Revenue This Year
$7.27
N/A
Revenue Next Year
$11.31
$62.75
P/E Ratio
$66.31
N/A
Revenue Growth
N/A
16.92
52 Week Low
$46.43
$6.83
52 Week High
$77.84
$28.24

Technical Indicators

Market Signals
Indicator
TFIN
NTLA
Relative Strength Index (RSI) 39.64 46.74
Support Level $53.88 $11.89
Resistance Level $61.89 $14.02
Average True Range (ATR) 2.17 1.05
MACD -0.79 -0.07
Stochastic Oscillator 13.11 41.11

Price Performance

Historical Comparison
TFIN
NTLA

About TFIN Triumph Financial Inc.

Triumph Financial Inc is a financial holding company. The company has four reportable segments namely Banking, Factoring, Payments, and Intelligence. The Banking segment includes the operations of TBK Bank. The Factoring segment includes the operations of Triumph Financial Services with revenue derived from factoring services, The Payments segment includes the operations of TBK Bank's TriumphPay division which provides a presentment, audit and payment solution to Shipper, Broker, and Factor clients in the trucking industry and The Intelligence segment includes to turn the over-the-road trucking data collected through the services into actionable insights for their customers.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: